Sultan Darvesh

List of Publications by Year
in descending order

126 papers	6,602 citations	117625 34 h-index	66911 78 g-index
155 all docs	155 docs citations	155 times ranked	7181 citing authors

#	Article	IF	Citations
1	Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. New England Journal of Medicine, 2005, 352, 2379-2388.	27.0	1,709
2	Neurobiology of butyrylcholinesterase. Nature Reviews Neuroscience, 2003, 4, 131-138.	10.2	719
3	Cholinesterases: Roles in the Brain During Health and Disease. Current Alzheimer Research, 2005, 2, 307-318.	1.4	303
4	Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study. Molecules, 2017, 22, 2098.	3.8	179
5	Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Journal of Neurosurgery, 2002, 96, 589-596.	1.6	145
6	Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiology of Aging, 2008, 29, 1285-1295.	3.1	138
7	Carbamates with Differential Mechanism of Inhibition Toward Acetylcholinesterase and Butyrylcholinesterase. Journal of Medicinal Chemistry, 2008, 51, 4200-4212.	6.4	136
8	Inhibition of Human Cholinesterases by Drugs Used to Treat Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2003, 17, 117-126.	1.3	134
9	Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 2009, 72, 2115-2121.	1.1	129
10	Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. , 1998, 393, 374-390.		127
11	Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 1173-1177.	1.4	126
12	Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. Journal of Comparative Neurology, 2003, 463, 25-43.	1.6	115
13	Butyrylcholinesterase Is Associated With Î²-Amyloid Plaques in the Transgenic APP_{SWE}/PSEN1dE9 Mouse Model of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 2-14.	1.7	114
14	Butyrylcholinesterase-knockout reduces brain deposition of fibrillar Î²-amyloid in an Alzheimer mouse model. Neuroscience, 2015, 298, 424-435.	2.3	109
15	Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell lineâ€derived neurotrophic factor in patients with Parkinson's disease. Journal of Neurosurgery, 2000, 92, 863-869.	1.6	106
16	A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clinica Chimica Acta, 2007, 378, 128-135.	1.1	95
17	Spectrum of Disease in Vascular Cognitive Impairment. Neuroepidemiology, 1999, 18, 248-254.	2.3	90
18	Sensitivity of butyrylcholinesterase knockout mice to (â^')-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology, 2007, 233, 60-69.	4.2	85

#	Article	IF	Citations
19	Butyrylcholinesterase and the cholinergic system. Neuroscience, 2013, 234, 53-68.	2.3	80
20	Cholinesterase Inhibition in Alzheimer's Disease: Is Specificity the Answer?. Journal of Alzheimer's Disease, 2014, 42, 379-384.	2.6	68
21	Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment. Journal of Molecular Neuroscience, 2003, 20, 241-248.	2.3	67
22	Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. Drugs of Today, 2004, 40, 711.	2.4	67
23	Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse. Current Alzheimer Research, 2014, 11, 450-460.	1.4	64
24	Estimating the Prevalence of Dementia in Elderly People: A Comparison of the Canadian Study of Health and Aging and National Population Health Survey Approaches. International Psychogeriatrics, 2001, 13, 169-175.	1.0	57
25	Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 491-505.	2.6	57
26	Structureâ€“activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 211-222.	3.0	55
27	An integrated proteomics approach shows synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model. Oncotarget, 2016, 7, 33627-33648.	1.8	55
28	Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorganic and Medicinal Chemistry, 2007, 15, 6367-6378.	3.0	52
29	Probing the Peripheral Site of Human Butyrylcholinesterase. Biochemistry, 2012, 51, 7046-7053.	2.5	50
30	The Behavioural Neurology Assessment. Canadian Journal of Neurological Sciences, 2005, 32, 167-177.	0.5	48
31	Reduced fibrillar Î²-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model. Chemico-Biological Interactions, 2016, 259, 307-312.	4.0	43
32	Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. Journal of Comparative Neurology, 1998, 393, 374-90.	1.6	42
33	On the active site for hydrolysis of aryl amides and choline esters by human cholinesterases. Bioorganic and Medicinal Chemistry, 2006, 14, 4586-4599.	3.0	41
34	Distribution of neuropeptide-like immunoreactivity in intact and chronically decentralized middle cervical and stellate ganglia of dogs. Journal of the Autonomic Nervous System, 1987, 21, 167-180.	1.9	38
35	Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chemico-Biological Interactions, 2010, 187, 425-431.	4.0	37
36	Subcortical Dementia: A Neurobehavioral Approach. Brain and Cognition, 1996, 31, 230-249.	1.8	35

#	Article	IF	Citations
37	Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues. Current Alzheimer Research, 2010, 7, 386-400.	1.4	35
38	2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease. Chemico-Biological Interactions, 2021, 335, 109348.	4.0	35
39	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorganic and Medicinal Chemistry, 2010, 18, 2232-2244.	3.0	34
40	Neuropathologic burden and the degree of frailty in relation to global cognition and dementia. Neurology, 2020, 95, e3269-e3279.	1.1	33
41	Differential effects of lipid-lowering agents on human cholinesterases. Clinical Biochemistry, 2004, 37, 42-49.	1.9	32
42	Retrospective Diagnosis of Dementia Using an Informant Interview Based on the Brief Cognitive Rating Scale. International Psychogeriatrics, 1998, 10, 53-60.	1.0	30
43	Inter-Rater Reliability of the Diagnosis of Vascular Cognitive Impairment at a Memory Clinic. Neuroepidemiology, 2000, 19, 186-193.	2.3	30
44	Butyrylcholinesterase and Cognitive Function. International Psychogeriatrics, 2001, 13, 461-464.	1.0	30
45	Improved prediction of early-onset coronary artery disease using APOE Îµ4, BChE-K, PPARÎ³2 Pro12 and ENOS T-786C in a polygenic model. Clinical Biochemistry, 2006, 39, 109-114.	1.9	30
46	An MRI Brain Atrophy and Lesion Index to Assess the Progression of Structural Changes in Alzheimer's Disease, Mild Cognitive Impairment, and Normal Aging: A Follow-Up Study. Journal of Alzheimer's Disease, 2011, 26, 359-367.	2.6	30
47	The Toronto Cognitive Assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment. Alzheimer's Research and Therapy, 2018, 10, 65.	6.2	30
48	Aryl acylamidase activity of human serum albumin witho-nitrotrifluoroacetanilide as the substrate. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 463-469.	5.2	29
49	A method to describe enzyme-catalyzed reactions by combining steady state and time course enzyme kinetic parameters. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 1-5.	2.4	29
50	Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin. Cellular and Molecular Neurobiology, 2001, 21, 285-296.	3.3	27
51	Butyrylcholinesterase-knockout reduces fibrillar Î²-amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimerâ€™s disease. Brain Research, 2017, 1671, 102-110.	2.2	27
52	Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 15758.	3.3	27
53	Kinetic analysis of butyrylcholinesterase-catalyzed hydrolysis of acetanilides. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 1139-1147.	2.3	26
54	An MRI-Based Semiquantitative Index for the Evaluation of Brain Atrophy and Lesions in Alzheimerâ€™s Disease, Mild Cognitive Impairment and Normal Aging. Dementia and Geriatric Cognitive Disorders, 2010, 30, 121-130.	1.5	26

#	Article	IF	Citations
55	Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APPSWE/PS1Î”E9 Transgenic Mice Implicate Cathepsin Z in Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2018, 12, 397.	3.7	26
56	Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimerâ€™s Disease Patients. Frontiers in Cellular Neuroscience, 2019, 13, 538.	3.7	25
57	The risk of dementia in relation to statins and other lipid lowering agents. Neurological Research, 2003, 25, 601-604.	1.3	24
58	A versatile equation to describe reversible enzyme inhibition and activation kinetics: Modeling Î²-galactosidase and butyrylcholinesterase. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 733-746.	2.4	24
59	Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. Journal of the Autonomic Nervous System, 1998, 71, 75-84.	1.9	22
60	Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. Biochimica Et Biophysica Acta - General Subjects, 2011, 1810, 1230-1235.	2.4	21
61	Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E Ïµ4 genes in early-onset coronary artery disease. Clinical Biochemistry, 2002, 35, 205-209.	1.9	20
62	Homocysteine Thiolactone and Human Cholinesterases. Cellular and Molecular Neurobiology, 2007, 27, 33-48.	3.3	20
63	Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 166-176.	3.7	19
64	Intact olfactory memory in the 5xFAD mouse model of Alzheimerâ€™s disease from 3 to 15 months of age. Behavioural Brain Research, 2020, 393, 112731.	2.2	19
65	Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase. Journal of Neural Transmission, 2007, 114, 939-945.	2.8	18
66	Butyrylcholinesterase radioligands to image Alzheimerâ€™s disease brain. Chemico-Biological Interactions, 2013, 203, 354-357.	4.0	18
67	An approach to the synthesis of bruceantin. The synthesis of a tetracyclic intermediate. Canadian Journal of Chemistry, 1989, 67, 2237-2240.	1.1	17
68	Human serum cholinesterase from liver pathological samples exhibit highly elevated aryl acylamidase activity. Clinica Chimica Acta, 2007, 380, 151-156.	1.1	15
69	Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3822-3825.	2.2	15
70	Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. Experimental Neurology, 2004, 188, 461-470.	4.1	14
71	Lipid-Lowering Agents and the Risk of Cognitive Impairment That Does Not Meet Criteria for Dementia, in Relation to Apolipoprotein E Status. Neuroepidemiology, 2007, 29, 201-207.	2.3	14
72	Limitations of conventional inhibitor classifications. Integrative Biology (United Kingdom), 2011, 3, 1197.	1.3	14

#	Article	IF	Citations
73	Synthetic studies towards bruceantin. Part 1. Establishment of the carbon network. Canadian Journal of Chemistry, 1991, 69, 712-722.	1.1	13
74	Synthesis and Preliminary Evaluation of Phenyl 4-¹²³I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology. Journal of Nuclear Medicine, 2016, 57, 297-302.	5.0	12
75	Clock Drawing Test in acute stroke and its relationship with long-term functional and cognitive outcomes. Clinical Neuropsychologist, 2019, 33, 817-830.	2.3	12
76	Cysteine Thioesters as Myelin Proteolipid Protein Analogues to Examine the Role of Butyrylcholinesterase in Myelin Decompaction. ACS Chemical Neuroscience, 2011, 2, 151-159.	3.5	11
77	Evidence for Cholinergic Dysfunction in Autosomal Dominant Kufs Disease. Canadian Journal of Neurological Sciences, 2018, 45, 150-157.	0.5	10
78	Reduced Serotonin Transporter Levels and Inflammation in the Midbrain Raphe of 12 Month Old APP_{swe}/PSEN_{1dE9} Mice. Current Alzheimer Research, 2018, 15, 420-428.	1.4	10
79	Spruce budworm: Roles of pheromone components and analogues in male disruption and attraction. Experientia, 1980, 36, 222-223.	1.2	9
80	Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases. Cellular and Molecular Neurobiology, 2003, 23, 93-100.	3.3	9
81	Potentially Procholinergic Effects of Medications Commonly Used in Older Adults. American Journal of Geriatric Pharmacotherapy, 2011, 9, 80-87.	3.0	8
82	Synthesis and Preliminary Evaluation of Piperidinyl and Pyrrolidinyl Iodobenzoates as Imaging Agents for Butyrylcholinesterase. Molecular Imaging and Biology, 2011, 13, 1250-1261.	2.6	8
83	1-(3-Tert-Butylphenyl)-2,2,2-Trifluoroethanone as a Potent Transition-State Analogue Slow-Binding Inhibitor of Human Acetylcholinesterase: Kinetic, MD and QM/MM Studies. Biomolecules, 2020, 10, 1608.	4.0	8
84	Imaging Butyrylcholinesterase in Multiple Sclerosis. Molecular Imaging and Biology, 2021, 23, 127-138.	2.6	8
85	Synthetic studies towards bruceantin. Part 2. The synthesis of a pentacyclic intermediate. Canadian Journal of Chemistry, 1991, 69, 723-731.	1.1	7
86	Progressive Anomia Without Semantic or Phonological Impairment. Cortex, 2007, 43, 558-564.	2.4	7
87	Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus. Neuropathology and Applied Neurobiology, 2017, 43, 571-583.	3.2	7
88	Information Processing and Magnetic Resonance Imaging Indices of Brain Pathology in Multiple Sclerosis. International Journal of MS Care, 2012, 14, 84-91.	1.0	7
89	Development of acetophenone ligands as potential neuroimaging agents for cholinesterases. Bioorganic and Medicinal Chemistry, 2016, 24, 5270-5279.	3.0	6
90	EFFECTS OF PHEROMONE, PHEROMONE COMPONENTS, AND PHEROMONE ANALOGUES ON MATING OF THE SPRUCE BUDWORM (LEPIDOPTERA: TORTRICIDAE). Canadian Entomologist, 1980, 112, 605-608.	0.8	5

#	Article	IF	Citations
91	Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia. Canadian Journal of Neurological Sciences, 2019, 46, 174-183.	0.5	4
92	Phenothiazines as dual inhibitors of SARS-CoV-2 main protease and COVID-19 inflammation. Canadian Journal of Chemistry, 2021, 99, 801-811.	1.1	4
93	Thioesters for the in vitro evaluation of agents to image brain cholinesterases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 447-455.	5.2	3
94	Peripheral Dysgraphia. Cognitive and Behavioral Neurology, 2014, 27, 31-47.	0.9	3
95	Mild Microglial Responses in the Cortex and Perivascular Macrophage Infiltration in Subcortical White Matter in Dogs with Age-Related Dementia Modelling Prodromal Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, 575-592.	2.6	3
96	Interaction of Exogenous Butyrylcholinesterase with Î²-Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain. Current Alzheimer Research, 2021, 18, 470-481.	1.4	3
97	Electroantennograms and Trapping with Spruce Budworm (Lepidoptera: Tortricidae) Sex Pheromone Analogues. Environmental Entomology, 1982, 11, 1285-1289.	1.4	2
98	Corticobasal Degeneration Substantiated by Imaging Studies. American Journal of Geriatric Psychiatry, 2005, 13, 333-334.	1.2	2
99	Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro. Neurobiology of Aging, 2021, 103, 31-41.	3.1	2
100	Alzheimerâ€™s Disease and Related Disorders Annual. 2000. Edited by Serge Gauthier, and Jeffery L. Cummings. Published by Martin Dunitz Ltd. 255 pages. C$102.00 approx.. Canadian Journal of Neurological Sciences, 2001, 28, 379-379.	0.5	1
101	P3-178 Butyrylcholinesterase activity in the human amygdala, hippocampal formation and the thalamus in Alzheimer's disease. Neurobiology of Aging, 2004, 25, S406.	3.1	1
102	S2-02-05 Use of lipid lowering agents and the risk of cognitive impairment, not dementiain relation to apolipoprotein E status. Neurobiology of Aging, 2004, 25, S27.	3.1	1
103	Disconnection of Language and Memory in Semantic Dementia: A Comparative and Theoretical Analysis. Current Alzheimer Research, 2005, 2, 435-448.	1.4	1
104	Tomographic visualization of cholinesterase. Annals of Neurology, 2006, 60, 745-746.	5.3	1
105	P1-261: CHANGES IN PREFRONTAL ACTIVATION IN EARLY ALZHEIMER'S DISEASE: A MAGNETOENCEPHALOGRAPHY (MEG) STUDY. , 2014, 10, P403-P404.		1
106	P1-210: Comparison of butyrylcholinesterase and Î²-amyloid as diagnostic markers for the definitive diagnosis of Alzheimer's disease. , 2015, 11, P431-P431.		1
107	ICâ€Pâ€163: Synthesis and In Vivo Spect Evaluation of a Novel Butyrylcholinesterase Diagnostic Radioligand for Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P120.	0.8	1
108	The cholinergic system in the basal forebrain of the Atlantic whiteâ€sided dolphin (Lagenorhynchus) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	1

#	Article	IF	Citations
109	Clinical and neuropathological variability in the rare IVS10Â+ 14 tau mutation. Neurobiology of Aging, 2021, 101, 298.e1-298.e10.	3.1	1
110	Corticobasal Degeneration Substantiated by Imaging Studies. American Journal of Geriatric Psychiatry, 2005, 13, 333-334.	1.2	1
111	Butyrylcholinesterase as a biomarker in Alzheimerâ€™s disease. , 2020, , 263-280.		1
112	P1-311: CLINICOPATHOLOGICAL CORRELATION OF NEURODEGENERATIVE CASES IN A DEMENTIA UNIT. , 2014, 10, P425-P426.		0
113	IC-P-098: ALTERNATIVE CEREBRAL GLUCOSE UPTAKE METRICS DETECT EARLY METABOLIC CHANGES IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P55-P55.		0
114	P1-296: ALTERNATIVE CEREBRAL GLUCOSE UPTAKE METRICS DETECT EARLY METABOLIC CHANGES IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P419-P419.		0
115	IC-P-022: Cerebral glucose metabolism in a 5XFAD butyrylcholinesterase-knockout mouse model of Alzheimer's disease. , 2015, 11, P25-P26.		0
116	P1-160: Cerebral glucose metabolism in a 5XFAD butyrylcholinesterase-knockout mouse model of Alzheimer's disease. , 2015, 11, P406-P406.		0
117	P1-030: Butyrylcholinesterase knockout reduces deposition of fibrillar b-amyloid in an Alzheimer's mouse model. , 2015, 11, P348-P348.		0
118	P3-261: Synthesis and IN VIVO Spect Evaluation of a Novel Butyrylcholinesterase Diagnostic Radioligand for Alzheimerâ€™S Disease. , 2016, 12, P932-P932.		0
119	[P3â€“190]: ALZHEIMER PATHOLOGY AND CHOLINESTERASES IN THE PRIMARY OLFACTORY GYRUS. Alzheimer's and Dementia, 2017, 13, P1007.	0.8	0
120	[ICâ€Pâ€023]: CEREBRAL PERFUSION IN THE 5XFAD MOUSE MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P24.	0.8	0
121	[P1â€“353]: CEREBRAL PERFUSION IN THE 5XFAD MOUSE MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P393.	0.8	0
122	ICâ€Pâ€065: BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P59.	0.8	0
123	P1â€424: BUTYRYLCHOLINESTERASE GENETIC POLYMORPHISM AND NEUROIMAGING BIOMARKERS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P468.	0.8	0
124	ICâ€Pâ€136: SYNTHESIS AND IN VIVO BRAIN PET EVALUATION OF 1â€METHYLâ€4â€PIPERIDYL Pâ€¹⁸[F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASEâ€SPECIFIC RADIOLIGAND FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P112.	0.8	0
125	A.03 Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia. Canadian Journal of Neurological Sciences, 2019, 46, S8.	0.5	0
126	Distribution of acetylcholinesterase in the hippocampal formation of the Atlantic whiteâ€sided dolphin (<scp>Lagenorhynchus acutus</scp>). Journal of Comparative Neurology, 2021, 529, 1029-1051.	1.6	0